000			05080nam a22003735i 4500
001			81979
003			ES-MaUEC
005			20230207040349.0
007			cr nn 008mamaa
008			141120s2015 xxu| s |||| 0|eng d
020			_a9781493913930
024	7		_a10.1007/978-1-4939-1393-0 _2doi
050		4	_aRC643 _b2015 EB
245	1	0	_aTargeted Therapy of Acute Myeloid Leukemia _cedited by Michael Andreeff.
260			_aNew York _bSpringer _c2015
300			_a1 recurso en línea (XIX, 826 páginas) _b62 ilustraciones, 46 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aCurrent Cancer Research
505	0		_aIntroduction/Perspective -- Genetics and Classification of Acute Myeloid Leukemia -- Proteomics of AML to guide Selection of Therapy -- Roles of Apoptosis Regulating Bcl-2-Family Genes in AML -- Bcl-2 family: Translational aspects -- IAP Family and Proteins as Therapeutic Targets for Acute Myeloid Leukemia -- TP53 Mutations in Acute Myeloid Leukemia -- Targeting p53 Tumor Suppressor for AML Therapy -- AML-Selective Apoptosis Induction by rationally designed Death Ligand Fusion Protein -- PIM Kinases in AML -- Development of Midostaurin as a Tyrosine Kinase Inhabitor -- FLT3 in AML -- FLT3-ITD. Clinical (Sorafenib/AC220) -- Nucleophosmin (NPM1) -- Raf/MEK Pathway -- The Role of Translational Medicine in Optimization of Therapies targeting the RAS-MAP Kinase Pathway -- Clinical Use of Farnesyltransferase Inhititors -- The P13K-AKT-mTOR signaling Network in AML -- Targeting the P13 Kinase-mTOR Signaling Pathway in AML -- Aurora kinases -- The Clinical Development of Aurora Kinase Inhibitors in Acute Myeloid Leukemia -- AML-Deacetylases -- Methylation in AML-Clinical Applications -- Topic: RARa/RXRÂСrt: Basic -- Arsenic Trioxide in Untreated APL -- Targeting PML-RARα with Retinoids -- NR4A Orphan Receptors as Drug Targets -- Antibody-based Therapeutics Targeting CD33, CD45, and CD66 -- New Heterogeneity of the Leukemic Stem Cells -- Targeting Leukemia Stem Cells -- Regulation of Hematopoiesis by CXCL12/CXCR4 Signaling -- CXC4/CXCL12 as a Therapeutic Target -- VLA-4: A Cellâ€{u3803}onsequential Encounter -- VLA-4 Function and Prognosis in Acute Myeloid Leukemia -- VLA4 in Acute Lymphoblastic Leukemia -- The Leukemic Bone Marrow Microenvironment: Targeting Hypoxia with Hypoxia Activated Pro-Drugs -- Topic: miRs as Therapeutic Targets -- Clinical Implications of MicroRNAs in AML -- Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid Leukemias -- Molecular and Biochemical Basis for the Reprogramming of Intermediary Metabolism in Leukemia Cells -- NK Cell Immunotherapy for AML -- Allogeneic and Autologous T cell Strategies to Enhance Targeting of Acute Myeloid Leukemia -- Indications for Hematopoietic Transplantation for AML -- Mesenchymal Stem/Stromal Cell Targeted Therapies for Solid Tumors and Hematological Malignancies.
520	3		_aThis book provides an unprecedented overview of targeted therapies for acute myeloid leukemias. The volume provides comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Authoritative chapters are written by leading research scientists and clinicians, who explain basic concepts and the clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML. The chapter topics include the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53, and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. In addition, chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells, and leukemia metabolism, provide insight into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies complete the overview of the multi-dimensional therapeutic landscape, whereÂ{u0B25}ukemia specialists develop treatment strategies, which are expected to bring forth critical breakthroughs in the field of leukemia.Â{uE033}
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
650		7	_aCitología _2embne _9139477
650	2	7	_aFarmacología _2embne _9137893
650		7	_aFarmacología _2embne _9137893
700	1		_aAndreeff, Michael _eeditor literario _994575 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4939-1393-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12906189 _b10-10-17 _c10-02-16
988			_aSpringer_Medicine_2015
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _gxxu _h0
945			_aRC643 .T374 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11573879 _z06-04-17
999			_c81979 _d81979 _x1